Utah made waves last month when the state announced it would let an AI chatbot autonomously order drugs for patients. The move struck some observers as something of a high-stakes gamble.
Nearly 40 healthcare organizations signed a letter in support of the bipartisan legislation, noting that Medicare's “efficiency adjustment” decreases reimbursement during a challenging time for physicians.
Medtronic's third quarter included a boom in PFA sales and a significant investment in Anteris Technologies. CEO Geoff Martha said the company hopes to make an even bigger impact in the structural heart space as time goes on.
The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR.
The Connecticut-based payer is labeling peripheral nerve stimulation, used to treat chronic pain, as medically unnecessary, with the Society of Interventional Radiology and others questioning the rationale.
Although serious adverse events related to COVID-19 vaccines are rare, some are life-threatening. It is important that radiologists are aware of how these complications present.
AI-enabled coronary plaque assessments deliver significant value, according to late-breaking data presented at TCT. These AI platforms have gained considerable momentum in recent months, receiving expanded Medicare coverage in addition to a new Category I CPT code.
Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology, said tricuspid valve treatments are a popular topic among cardiologists right now. TAVR research, meanwhile, remains as important as ever.
Utah made waves last month when the state announced it would let an AI chatbot autonomously order drugs for patients. The move struck some observers as something of a high-stakes gamble.
